Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis-An Observational Pilot Study

Overview

Journal Front Pediatr

Specialty Pediatrics

Date 2022 May 9

PMID 35529332

Authors

Insa Korten

Elisabeth Kieninger

Linn Krueger

Marina Bullo

Christa E Fluck

Philipp Latzin

Carmen Casaulta

Claudia Boettcher

Affiliations

Soon will be listed here.

Abstract

Background: The effect of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on glucose tolerance and/or cystic-fibrosis-related diabetes (CFRD) is not well understood. We performed an observational study on the short-term effects of ELX/TEZ/IVA on glucose tolerance.

Methods: Sixteen adolescents with CF performed oral glucose tolerance tests (OGTT) before and 4-6 weeks after initiating ELX/TEZ/IVA therapy. A continuous glucose monitoring (CGM) system was used 3 days before until 7 days after starting ELX/TEZ/IVA treatment.

Results: OGTT categories improved after initiating ELX/TEZ/IVA therapy ( = 0.02). Glucose levels of OGTT improved at 60, 90, and 120 min ( < 0.05), whereas fasting glucose and CGM measures did not change.

Conclusion: Shortly after initiating ELX/TEZ/IVA therapy, glucose tolerance measured by OGTT improved in people with CF. This pilot study indicates that ELX/TEZ/IVA treatment has beneficial effects on the endocrine pancreatic function and might prevent or at least postpone future CFRD.

Citing Articles

Proteomics profiling of inflammatory responses to elexacaftor/tezacaftor/ivacaftor in cystic fibrosis.

Ozuna H, Bojja D, Partida-Sanchez S, Hall-Stoodley L, Amer A, Britt Jr R Front Immunol. 2025; 16:1486784.

PMID: 39935472 PMC: 11811078. DOI: 10.3389/fimmu.2025.1486784.

Highly effective cystic fibrosis transmembrane conductance (regulator) modulator therapy: shifting the curve for most while leaving some further behind.

Chun S, Somers M, Burgener E Curr Opin Pediatr. 2024; 36(3):290-295.

PMID: 38411576 PMC: 11042992. DOI: 10.1097/MOP.0000000000001338.

Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis.

Xu W, Wu T, Zhou Z, Zuo Z Front Pharmacol. 2024; 14:1275470.

PMID: 38186649 PMC: 10768559. DOI: 10.3389/fphar.2023.1275470.

An Update in Cystic Fibrosis-Related Diabetes in Children and Adolescents.

Anton-Paduraru D, Murgu A, Donos M, Trofin F, Azoicai A, Popovici P Children (Basel). 2023; 10(12).

PMID: 38136081 PMC: 10741586. DOI: 10.3390/children10121879.

Oxidative Stress Biomarkers in Cystic Fibrosis and Cystic Fibrosis-Related Diabetes in Children: A Literature Review.

Pinzaru A, Mihai C, Chisnoiu T, Pantazi A, Lupu V, Kassim M Biomedicines. 2023; 11(10).

PMID: 37893045 PMC: 10604378. DOI: 10.3390/biomedicines11102671.

References

Lewis C, Blackman S, Nelson A, Oberdorfer E, Wells D, Dunitz J . Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med. 2014; 191(2):194-200. PMC: 4347432. DOI: 10.1164/rccm.201403-0576OC. View

Hayes Jr D, McCoy K, Sheikh S . Resolution of cystic fibrosis-related diabetes with ivacaftor therapy. Am J Respir Crit Care Med. 2014; 190(5):590-1. DOI: 10.1164/rccm.201405-0882LE. View

Guo J, Chen H, Ruan Y, Zhang X, Zhang X, Fok K . Glucose-induced electrical activities and insulin secretion in pancreatic islet β-cells are modulated by CFTR. Nat Commun. 2014; 5:4420. PMC: 4104438. DOI: 10.1038/ncomms5420. View

Misgault B, Chatron E, Reynaud Q, Touzet S, Abely M, Melly L . Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients. J Cyst Fibros. 2020; 19(5):712-716. DOI: 10.1016/j.jcf.2020.03.002. View

Zemanick E, Taylor-Cousar J, Davies J, Gibson R, Mall M, McKone E . A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One Allele. Am J Respir Crit Care Med. 2021; 203(12):1522-1532. PMC: 8483230. DOI: 10.1164/rccm.202102-0509OC. View

Beaudoin N, Bouvet G, Coriati A, Rabasa-Lhoret R, Berthiaume Y . Combined Exercise Training Improves Glycemic Control in Adult with Cystic Fibrosis. Med Sci Sports Exerc. 2016; 49(2):231-237. DOI: 10.1249/MSS.0000000000001104. View

Heijerman H, McKone E, Downey D, Van Braeckel E, Rowe S, Tullis E . Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019; 394(10212):1940-1948. PMC: 7571408. DOI: 10.1016/S0140-6736(19)32597-8. View

Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A . Standardisation of spirometry. Eur Respir J. 2005; 26(2):319-38. DOI: 10.1183/09031936.05.00034805. View

Hart N, Aramandla R, Poffenberger G, Fayolle C, Thames A, Bautista A . Cystic fibrosis-related diabetes is caused by islet loss and inflammation. JCI Insight. 2018; 3(8). PMC: 5931120. DOI: 10.1172/jci.insight.98240. View

10.

Foster K, Huang G, Zhang N, Crisalli J, Chini B, Amin R . Relationship between exercise capacity and glucose tolerance in cystic fibrosis. Pediatr Pulmonol. 2017; 53(2):154-161. DOI: 10.1002/ppul.23906. View

11.

Uc A, Olivier A, Griffin M, Meyerholz D, Yao J, Abu-El-Haija M . Glycaemic regulation and insulin secretion are abnormal in cystic fibrosis pigs despite sparing of islet cell mass. Clin Sci (Lond). 2014; 128(2):131-42. PMC: 4346161. DOI: 10.1042/CS20140059. View

12.

Robinson P, Latzin P, Verbanck S, Hall G, Horsley A, Gappa M . Consensus statement for inert gas washout measurement using multiple- and single- breath tests. Eur Respir J. 2013; 41(3):507-22. DOI: 10.1183/09031936.00069712. View

13.

White M, Maheshwari R, Anderson S, Berlinguer-Palmini R, Jones C, Richardson S . In Situ Analysis Reveals That CFTR Is Expressed in Only a Small Minority of β-Cells in Normal Adult Human Pancreas. J Clin Endocrinol Metab. 2019; 105(5). PMC: 7341165. DOI: 10.1210/clinem/dgz209. View

14.

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2019; 43(Suppl 1):S14-S31. DOI: 10.2337/dc20-S002. View

15.

Yaribeygi H, Farrokhi F, Butler A, Sahebkar A . Insulin resistance: Review of the underlying molecular mechanisms. J Cell Physiol. 2018; 234(6):8152-8161. DOI: 10.1002/jcp.27603. View

16.

Olivier A, Yi Y, Sun X, Sui H, Liang B, Hu S . Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets. J Clin Invest. 2012; 122(10):3755-68. PMC: 3534166. DOI: 10.1172/JCI60610. View

17.

Frauchiger B, Carlens J, Herger A, Moeller A, Latzin P, Ramsey K . Multiple breath washout quality control in the clinical setting. Pediatr Pulmonol. 2020; 56(1):105-112. DOI: 10.1002/ppul.25119. View

18.

Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W . Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009; 32(9):1626-31. PMC: 2732133. DOI: 10.2337/dc09-0586. View

19.

Southern K, Murphy J, Sinha I, Nevitt S . Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020; 12:CD010966. PMC: 8094390. DOI: 10.1002/14651858.CD010966.pub3. View

20.

Schmid K, Fink K, Holl R, Hebestreit H, Ballmann M . Predictors for future cystic fibrosis-related diabetes by oral glucose tolerance test. J Cyst Fibros. 2013; 13(1):80-5. DOI: 10.1016/j.jcf.2013.06.001. View